Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population The Zhuiguang Trial

Exclusion Criteria

• •1. Contraindications to conventional laser trabeculoplasty (e.g., corneal abnormalities, etc.)
• •2. Angle Closure Glaucoma
• •3. Congenital or developmental glaucoma
• •4. Secondary glaucoma except exfoliative or pigmentary glaucoma
• •5. Presence of any Peripheral Anterior Synechiae (PAS) in the study eye
• •6. Inability to conduct a reliable visual field (defined as fixation losses, false positives or false negatives greater than 33%)
• •7. Any of the following visual field findings using the Humphrey visual field analyzer the SITA-standard 24-2 program:
• •1. A visual field MD of worse than -12dB
• •2. Greater than or equal to 75% of points depressed below the 5% level and greater than or equal to 50% of points depressed below the 1% level on the PD plot.
• •3. At least 50% of points (i.e 2 or more) within the central 5 degrees with a sensitivity ≤0dB on the decibel plot
• •4. Points within the central 5 degrees of fixation with a sensitivity \<15 dB in both hemifields on the decibel plot
• •8. A visual field MD of worse than -12dB in the fellow eye
• •9. Cup:Disc Ratio of more than 0.8
• •10. More than three hypotensive medications required (combination drops are considered as 2 medications)
• •11. Prior incisional or laser glaucoma surgery (including previous SLT or LPI) in the study eye.
• •12. Prior corneal refractive surgery
• •13. Complicated cataract surgery ≤ 6 months prior to enrollment
• •14. Presence of visually significant cataract in the opinion of the investigator
• •15. Clinically significant disease in either eye as determined by the Investigator.
• •16. Clinically significant amblyopia in either eye
• •17. Dense pigmentation or haemorrhage in the peri-limbal conjunctiva or anterior sclera
• •18. Women who are pregnant or may become pregnant during the course of the study.
• •19. In the opinion of the investigator the participant might require other ocular surgery within the 12-month follow-up period, unless for further reduction of their IOP
• •20. Concurrent treatment with topical, nasal, inhaled or systemic steroids.
• •21. Uncontrolled systemic disease that could impact the ability of the participant to attend follow up visits as per the discretion of the investigator.
• •22. Participation in another clinical study, not including a GLAUrious sub-study